Department of Radiology, University of Minnesota Medical School, MMC 292 Mayo Memorial Building, 420 Delaware Street S.E., Minneapolis, MN 55455, USA.
Diagnostics (Basel). 2013 Mar 15;3(1):170-91. doi: 10.3390/diagnostics3010170.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed.
肝细胞癌 (HCC) 是最常见的肝癌形式，也是全球癌症相关死亡的第三大主要原因。由于 HCC 通常在晚期诊断，因此治疗选择非常有限。最近的研究表明，微小 RNA (miRNA)，一类非编码 RNA，在 HCC 中异常表达。其中一些被证明在致癌和肿瘤进展中具有功能作用，表明 miRNA 可以作为 HCC 治疗的新分子靶点。最近的一些有前途的研究表明，miRNA 在动物模型中以及在降低丙型肝炎患者病毒载量方面具有治疗潜力。在这篇综述中，讨论了用于体内治疗性递药和替代治疗的 miRNA 调节的这些进展和策略。
